Oncotarget

Research Papers:

Fibroblast growth factor receptor 1 (FGFR1) as a therapeutic target in adenoid cystic carcinoma of the lacrimal gland

Ravi Doddapaneni, Wensi Tao, Andrea Naranjo, Neda Nikpoor, David T. Tse, Daniel Pelaez _

PDF  |  HTML  |  Order a Reprint

Oncotarget. 2019; 10:480-493. https://doi.org/10.18632/oncotarget.26558

Metrics: PDF 131 views  |   HTML 195 views  |   ?  


Abstract

Ravi Doddapaneni1,*, Wensi Tao1,*, Andrea Naranjo1, Neda Nikpoor1, David T. Tse1 and Daniel Pelaez1,2,3,4

1Dr. Nasser Al-Rashid Orbital Vision Research Center, Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami Miller School of Medicine, Miami, FL 33136, USA

2Department of Biomedical Engineering, University of Miami Miller School of Medicine, Miami, FL 33136, USA

3Department of Cell Biology, University of Miami Miller School of Medicine, Miami, FL 33136, USA

4Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA

*Equal first author contribution

Correspondence to:

Daniel Pelaez, email: dpelaez@miami.edu

Keywords: adenoid cystic carcinoma; lacrimal gland; FGFR; targeted therapy; precision medicine

Received: October 30, 2018    Accepted: December 20, 2018    Published: January 11, 2019

ABSTRACT

Identification of molecular targets is the first step in developing efficacious therapeutic strategies for tumors. A tumors’ biological response to perturbagens yields important information on the molecular determinants for tumor growth. The aim of this study was to characterize the response of adenoid cystic carcinoma of the lacrimal gland (LGACC) to intra-arterial cytoreductive chemotherapy (IACC) in order to identify novel targets to enhance therapy. We performed high-throughput proteomic analysis on paired samples from pre-IACC diagnostic biopsies and post-IACC excised tumor samples from 6 LGACC patients. This proteomic analysis provides a comprehensive landscape of the cellular compartments contained within the excised tumors. Interestingly, we found a strong upregulation across the fibroblast growth factor (FGF) signaling pathway, with FGF receptor 1 (FGFR1) exhibiting a consistent and significant upregulation in all post-IACC samples. We thus evaluated the therapeutic efficacy of a novel FGFR1 selective inhibitor, AZD4547, in combination with cisplatin on LGACC cells in-vitro. The combination index (CI) value (<0.895) demonstrated synergistic effect of AZD4547 and cisplatin in inhibiting cell growth and viability (p<0.02), with a differential response seen in post-IACC cultures when compared to pre-IACC cultures. The combination approach showed synergy of the drugs in the migration assay. Western blot analysis indicated a significant upregulation of cleaved caspase-3 and downregulation the expression of FGFR1 (p<0.05) with the combination treatment as compared to either agent independently. Our findings demonstrate that FGFR1 inhibition potentiates the cytoreductive effects of cisplatin and suggest a potential therapeutic benefit of using AZD4547 in the management of LGACC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 26558